Ascentage Pharma Group International (AAPG) Long-Term Deferred Tax (2022 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $6.3 million as the latest value for Q4 2025.
- For Q4 2025, Long-Term Deferred Tax rose 2.5% year-over-year to $6.3 million; the TTM value through Dec 2025 reached $6.3 million, up 2.5%, while the annual FY2025 figure was $4.6 million, 24.59% down from the prior year.
- Long-Term Deferred Tax hit $6.3 million in Q4 2025 for Ascentage Pharma Group International, up from $6.2 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $155.5 million in Q4 2023 and bottomed at $6.2 million in Q4 2024.
- Average Long-Term Deferred Tax over 4 years is $44.1 million, with a median of $7.3 million recorded in 2022.
- Year-over-year, Long-Term Deferred Tax soared 1755.42% in 2023 and then crashed 96.04% in 2024.
- Ascentage Pharma Group International's Long-Term Deferred Tax stood at $8.4 million in 2022, then skyrocketed by 1755.42% to $155.5 million in 2023, then crashed by 96.04% to $6.2 million in 2024, then grew by 2.5% to $6.3 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $6.3 million, $6.2 million, and $155.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.